Rational design of Harakiri (HRK)-derived constrained peptides as BCL-x L inhibitors.

Using the HRK BH3 domain, sequence hybridization and in silico methods we show dibromomaleimide staple scanning can be used to inform the design of BCL-x L selective peptidomimetic ligands. These HRK-inspired reagents may serve as starting points for the discovery of therapeutics to target BCL-x L -overexpressed cancers.